Organizing committee at imed.ulisboa/ffulisboa Joao Goncalves (Coordinator) and Paula Brito.
|
|
- Christine Floyd
- 6 years ago
- Views:
Transcription
1 PhD Programme in Medicines and Pharmaceutical Innovation Course BioPharmaceuticals and Advanced Therapies Lisbon, 18, 19, 20 and 25, 26 September 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal Organizing committee at imed.ulisboa/ffulisboa Joao Goncalves (Coordinator) and Paula Brito. The FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3du; trains students in target discovery, drug design, preclinical development, and drug safety, bridging the translational gap from discoveries on disease targets and mechanisms into novel diagnostic and therapeutic agents. Programme The Course on BioPharmaceuticals and Advanced Therapies is part of the PhD Programme in Medicines and Pharmaceutical Innovation (i3du), provides an overview of both classical and biotechnology derived medicinal products and on the pathways used for scientific advice, clinical trials and marketing authorizations in Europe. The course will also cover in detail the particular requirements for the CMC section, comparability packages and important safety procedures. The particular aspects of the non-clinical and clinical development of biopharmaceuticals will be presented. Case studies discussing how to develop proteins or cell therapies, such as monoclonal antibodies will illustrate the approach taken to identify benefit/risk ratio. An overview will be given on the most essential issues relating to Advanced Therapy Medicinal Products (ATMPs). A detailed presentation of the specific considerations for the development of biosimilar medicinal products, will be given during the course. The training program welcomes the participation of external academic and scientific community members. The course will be held at the Research Institute for Medicines (imed.ulisboa), Faculdade de Farmácia, Universidade de Lisboa, in Lisbon, 18-20, 25 and 26 September The training program is aimed at PhD students, but welcomes the participation of external academic and scientific community members. Registration ( is free but mandatory. 1
2 September 18, Drug Discovery and Development 9:30h The different classes of biopharmaceuticals 10.30h Discovery of Antibodies by Phage Display Soraia Oliveira - 11:30h Microfluidics as a discovery and diagnostic tool for biopharmaceuticals Joao Pedro Conde INESC-MN and Department of Bioengineering. Instituto Superior Técnico 14:00h Biopharmaceutical discovery in cancer Antonio Duarte- Faculdade Medicina Veterinária da Universidade de Lisboa 15:00h Steps in the discovery of a vaccine: the case of HIV Nuno Taveira Instituto Superior de Ciências da Saúde Egas Moniz Research Institute for Medicines (imed.ulisboa), September 19, Discovery and Therapeutic Applications of Biopharmaceuticals 9:30h Stem cell systems and 3D technologies: Possible application in biopharmaceuticals toxicology Joana Miranda, Research Institute for Medicines (imed.ulisboa), 10.30h In vivo models for biopharmaceutical discovery Sandra Aguiar- Faculdade Medicina Veterinária da Universidade de Lisboa 11:30h Antibody Drug Conjugates Pedro Gois, Research Institute for Medicines (imed.ulisboa), Faculty of Pharmacy, Universidade de Lisboa 14:00h The concept and advancements of Immunotherapy 2
3 15:00h Biopharmaceutical therapy in autoimmune diseases Jose Alves - NOVA Medical School / CEDOC, Lisbon. Director of Internal Medicine Dept. Fernando Fonseca Hospital September 20, Production and development aspects of biopharmaceuticals 9:30h Production methodologies for biopharmaceuticals and regulatory environment Maria Henriques Ribeiro, Research Institute for Medicines (imed.ulisboa), 10.30h Formulation of biopharmaceuticals Joao Nuno Moreira CNC and Faculdade Farmácia da Universidade de Coimbra 11:30h New technologies for biopharmaceutical purification Cecilia Roque - UCIBIO, REQUIMTE, Departamento de Química Faculdade de Ciências e Tecnologia Universidade Nova de Lisboa 14:00h Pre-clinical Development of Biopharmaceuticals Sofia Corte-Real TechnoPhage and Faculty of Pharmacy, Universidade de Lisboa 15:00h Methodologies for Drug Clinical Development Jose Mata Faculdade de Medicina Dentária da Univ de Lisboa September 25, Development Issues of Advanced Therapies 09:30h Pharmacokinetics of Biopharmaceuticals Nuno Elvas - Research Institute for Medicines (imed.ulisboa), Faculty of Pharmacy, Universidade de Lisboa 10:30h Immunogenicity of Biopharmaceuticals. 11:30h Gene therapy and applications in neurologic diseases Luís Almeida, Center for Neurosciences and Cell Biology (CNC) and Faculty of Pharmacy, Universidade de Coimbra 3
4 14:00h Developments of phage therapy, Research Institute for Medicines (imed.ulisboa), 15:10h Regulatory overview of advanced therapies Margarida Menezes Ferreira Infarmed and European Medicines Agency. 16:00h Discussion September 26, Regulatory and Industrial view of Biopharmaceuticals 10:00h First in man testing of biopharmaceuticals Beatriz Lima - Research Institute for Medicines (imed.ulisboa), 11:00h Clinical Development and Medical Affairs in the biopharmaceutical industry Eduardo Ribeiro Medical Director at Abbvie Portugal. 12:00h Cell therapy: The experience from the biopharmaceutical company. Pedro Cruz - ECBio 14:00h The case of biopharmaceutical pipeline for solid tumors Ricardo Pacheco Novartis 15:00h The entrance of biosimilars in the biopharmaceutical industry Cátia Cantante - Biogen 16:00h Discussion Assessment (i3du 1 st Year PhD students ONLY) Assessment of the course consists in the preparation and submission of a research project, characters long (including spaces). Students are grouped to build multidisciplinary teams. Each group works throughout the week on a research project that should reflect the topic of the course, including methodologies and strategies to solve an innovative research question. The project is expected to adhere to the following general structure: a) Title; b) Conceptual hurdle and innovative idea to be tested; c) Plan and methods: d) Relevance of the project (scientific and social impact). 4
5 The students will select a broad topic of research and are expected to propose a specific project. This project will be evaluated according to the following criteria and weight: a) Novelty and relevance (30%); b) approach to the problem (30%); c) multidisciplinarity of the research plan (40%). 5
Course ADVANCED DRUG DELIVERY July 03-07, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal
PhD Programme in Medicines and Pharmaceutical Innovation Course ADVANCED DRUG DELIVERY July 03-07, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal Organizing committee at imed.ulisboa/ffulisboa
More informationFCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)
FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course BIOMARKERS AND ASSAY DEVELOPMENT February 6-10, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal The FCT
More informationFCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)
FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course ADVANCED DRUG DELIVERY September 17-21, 2018 Faculty of Pharmacy Amphitheatre B, Portugal Coordinator: António Almeida The course
More informationWORKSHOP ON NUCLEAR MOLECULAR IMAGING
WORKSHOP ON NUCLEAR MOLECULAR IMAGING (sponsored by the IAEA) Campus Tecnológico e Nuclear Instituto Superior Técnico, Universidade de Lisboa 5 th - 6 th December 2016 WORKSHOP ON NUCLEAR MOLECULAR IMAGING
More informationWe welcome the participation of external academic and scientific community members. Registration is free but mandatory.
FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course PHARMACEUTICAL BIOPHYSICS January 09-11 and 28-29, 2019 Faculty of Pharmacy Amphitheatre B (9-10 JAN) Room C.2.5 (11 JAN) Laboratories
More informationCurriculum vitae. Research Gate:
Curriculum vitae Personal/contact information Name: Nelson Santos Monteiro Date of birth: 6/5/1984 Nationality: Cape Verdean/Portuguese Email: nelson.monteiro@gmail.com LinkedIn contact: pt.linkedin.com/pub/nelson-monteiro/21/664/162/
More informationtraining programme in pharmaceutical medicine Translational MEDICINE
training programme in pharmaceutical medicine Translational MEDICINE BIOCANT Cantanhede 17-19 may 2012 Translational MEDICINE 17 19 may 2012 LocaL: BIOCANT - Cantanhede module Leader: carlos Faro, Phd
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationOVERVIEW. ibet MISSION AND OBJECTIVES
OVERVIEW MISSION AND OBJECTIVES Created in 1989, the Instituto de Biologia Experimental e Tecnológica () is a private non profit institution. A Biotechnology Research Organisation, interfaces between academic
More informationAPIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION
APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION 2017 ABOUT US Portuguese Pharmaceutical Industry Association Founded in 1975, succeeds the National Guild of the Manufacturers of Medicinal Products
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationtraining programme in pharmaceutical medicine clinical development
training programme in pharmaceutical medicine clinical development 25-27 nov 2010 clinical development 25 27 november 2010 Local: INFARMED, Lisboa Curricular Unit Leader: Miguel Forte, MD, PhD Lecturers:
More informationIMMUNOTHERAPY 2008: IMPLEMENTING COMBINATIONS
8 th International Workshop IMMUNOTHERAPY 2008: IMPLEMENTING COMBINATIONS Organized by: International Union Against Cancer (UICC) Center of Molecular Immunology Cuba, November 10-14, 2008 (http://www.uicc.org)
More informationtraining programme in pharmaceutical medicine clinical pharmacology
training programme in pharmaceutical medicine clinical pharmacology 04-06 nov 2010 clinical pharmacology 04 06 NOVEMBER 2010 Local: University of Aveiro, Campus Universitário de Santiago Curricular Unit
More informationIndia as an Outsourcing Frontier in Biotechnology
1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation
More informationBiopharmaceuticals A Regulatory Perspective
Biopharmaceuticals A Regulatory Perspective Maeve Lally Senior Pharmaceutical Assessor (Biologics) CASSS CMC Forum Killarney May 2017 Cead Mile Fáilte A hundred thousand welcomes 26/06/2017 2 Disclaimer
More informationConference Calendar. healthtech.com. January High-Content Analysis January 8-11 San Francisco, CA
High-Content Analysis January 8-11 San Francisco, CA www.highcontentanalysis.com January 2013 PepTalk January 21-25 Palm Springs, CA www.chi-peptalk.com January 24-25 Pipeline 1: Formulation: Optimizing
More informationBioProcess Technology Consultants, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994
, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994 Who We Are The biopharmaceutical and biotherapeutic development experts We are a team of results-oriented professionals assisting
More informationBiomolecular Characterization for Rational Drug Design. Maria João Romão
Biomolecular Characterization for Rational Drug Design Maria João Romão UCIBIO@REQUIMTE Applied Molecular Biosciences Unit Chemistry Department - FCT NOVA mjr@fct.unl.pt / http://sites.fct.unl.pt/xtal
More informationSpeakers Title & Biography
Speakers Title & Biography Dr. Janice M. Soreth Deputy Director, FDA Europe Office/CDER, Liaison to EMA Dr. Soreth 20-year agency veteran with unparalleled experience, including serving as CDER's director
More informationDiploma (Base Course) in Medicines Development
INTRODUCTION The participation in PharmaTrain Project determines the design of the Master in Medicines Development, adapting the syllabus defined in the European project to the current needs of the Spanish
More informationFormulário de acesso a dados do Registo Nacional de Doentes Reumáticos (Reuma.pt) da SPR
Formulário de acesso a dados do Registo Nacional de Doentes Reumáticos (Reuma.pt) da SPR 1. Title Efficacy and safety of biosimilar infliximab CT-P13 compared to originator infliximab in rheumatoid arthritis
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationBiotech Showcase 2016
1 Biotech Showcase 2016 Our Value Proposition Advancing broad product pipeline of biosimilars and next generation antibody therapeutics Proven track record in superior quality, efficient R&D and manufacturing
More information2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth
2009 INVESTOR DAY BioPharmaceuticals Ken Frank President BioPharmaceuticals December 17, 2009 Sustainable, Profitable Growth Life Sciences FY 2009 Total Sales $2,329.2 (amounts shown in millions) BioPharmaceuticals
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationCONTRACT RESEARCH SERVICES
1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply
More informationUpdate on the new immunogenicity guideline in the EU
Update on the new immunogenicity guideline in the EU draft 2016 EBF, Lisbon 27 th September 2016 Venke Skibeli, Senior Scientist, PhD Norwegian Medicines Agency, Member of the CHMP - BMWP, EMA, London
More information5 key characteristics
Biosimilars 5 key characteristics Biologics are medicinal products derived from living organisms. 1 Their use has impacted the treatment of a variety of diseases. 1 Patents for many biologics will soon
More informationOn the complexity of production planning and scheduling in the pharmaceutical industry: the Delivery Trade-offs Matrix
Krist V. Gernaey, Jakob K. Huusom and Rafiqul Gani (Eds.), 12th International Symposium on Process Systems Engineering and 25th European Symposium on Computer Aided Process Engineering. 31 May 4 June 2015,
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationPharmacy. i3l PHARMACY BACHELOR PROGRAM. The architect of drugs. Improving the Quality of Life
i3l PHARMACY BACHELOR PROGRAM The architect of drugs Improving the Quality of Life Pharmacy Message From the Head of Study Program Pharmaceutical products are essential to support various human health
More informationWeek 1: Discovery Biology Basic knowledge and tools used in Research and Development
Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges
More informationScientific Program. Thursday, November 16
Page 1 of 5 Hotel ALDEIA DOS CAPUCHOS, GOLF & SPA, Largo Aldeia dos Capuchos, Caparica, 9:30 Registration Opening Thursday, November 16 10:00 Cytogenetics and Molecular Genetics Club Hildeberto Correia
More informationAT A GLANCE. inventivhealthclinical.com
AT A GLANCE inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 PHASE I-IIA 03 PHASE IIB-III 04 LATE STAGE 05 STRATEGIC RESOURCING 06 BIOANALYTICAL 07 QUALITY ASSURANCE 08 CONSULTING 09 THERAPEUTIC
More informationBioProcess Technology Group. Helping Clients De-Risk Biopharmaceutical Development Since 1994
Helping Clients De-Risk Biopharmaceutical Development Since 1994 Who We Are The biopharmaceutical and biotherapeutic development experts We are a team of results-oriented professionals assisting clients
More informationNIAID Resources to Facilitate Medical Countermeasure Development
NIAID Resources to Facilitate Medical Countermeasure Development Paula Bryant, Ph.D. Senior Scientific Officer Concept Acceleration Program Biodefense, Research Resources, and Translational Research (OBRRTR)
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationBIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS
BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS Supported By: Organised By: PROGRAMME OVERVIEW BIOLOGICS MAKE UP MORE THAN 1,000 MEDICINES AND VACCINES THAT TARGET MORE THAN 100 DISEASES. Unlike medicines
More informationEXPERT COLLECTION. Explore our leading medical review series
EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,
More informationHandbook of Research on
Handbook of Research on Information Architecture and Management in Modern Organizations George Leal Jamil Informagöes em Rede, Brazil Jose Pogas-Rascäo Polytechnic Institute ofsetübal, Fernanda Ribeiro
More informationIntegration of FDSS7000 into a modular robotic system for Open Innovation drug discovery
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation
More informationMilano, September 7 th 2016
Milano, September 7 th 2016 Dear IRDiRC Consortium Assembly, I would be delighted to share with the IRDIRC Therapeutic Scientific Committee my knowledge and expertise in both fields of regulatory affairs
More informationReform of Biological Products Review with a Focus on CMC
Reform of Biological Products Review with a Focus on CMC Office of Pharmaceutical Science of Biological Products Center for Drug Evaluation (CDE) of CFDA Min Li WCBP, Jan 2018 Outline Background of Drug
More informationThe EIMPack Project. The Economic Impact of the Packaging and Packaging Waste Directive
The EIMPack Project The Economic Impact of the Packaging and Packaging Waste Directive Nuno Ferreira da Cruz Pedro Simões Sandra Ferreira Marta Cabral Rui Cunha Marques 24 January 2013 Luxembourg The Project
More informationGene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
More informationCharacterization of antiproliferative potential and biological targets of a copper
SUPPLEMENTARY MATERIAL Characterization of antiproliferative potential and biological targets of a copper compound containing 4 -phenyl terpyridine Ana Soraia Mendo 1, Sara Figueiredo 1,2, Catarina Roma-Rodrigues
More informationMaster of Science in Translational Biotechnology
Master of Science in Translational Biotechnology MS Translational Biotechnology Keck School of Medicine of USC University of Southern California Harlyne J. Norris Cancer Research Tower 1450 Biggy Street,
More informationIndividualised medicine: regulatory challenges
www.pei.de Individualised medicine: regulatory challenges Outline Revision IVD Directive Opportunities and challenges Possibilities for interaction http://upload.wikimedia.org/wikipedia/commons/thumb/6/66/gummy_bears.jpg
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationPharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA
Pharmceutical Toxicology: Tentative Agenda Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics December 3-4, 2012 PERI Training Facility ~ Arlington, VA Monday,
More informationi3du - PhD Programme in Medicines and Pharmaceutical Innovation First Report January 2015 June 2016 Faculty of Pharmacy, Universidade de Lisboa
i3du - PhD Programme in Medicines and Pharmaceutical Innovation First Report January 2015 June 2016 Faculty of Pharmacy, Universidade de Lisboa 1. Summary description 2. Activities 3. Facts and numbers
More informationGlobal Development Challenges: Classical and Advanced Therapy Medicinal products
Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationYour partner for successful biopharmaceutical development and approval
Your partner for successful biopharmaceutical development and approval About the Founders Experienced experts with unique agency and industry backgrounds Dr. Gabriele Dallmann + 25 years of experience
More informationMultidisciplinary master and doctoral programmes at the University of Lisbon
Multidisciplinary master and doctoral programmes at the University of Lisbon J.M. Serra Head of Department of Geographical Engineering, Geophysics and Energy Coordinator of the PhD doctoral program on
More informationCMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration
CMC Strategy Forum Japan 2015 9-10 November 2015 Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration 1 1. Background 2. Organization Chart 3. Biological Products 4. Regulation
More informationSuccessful Academia-Pharma Collaboration Drug Discovery and Clinical Development
Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Toshio MIYATA Tohoku University Graduate School of Medicine United Centers for Advanced Research and Translational Medicine
More informationBIOPHARMACEUTICALS Availability, Diffusion, Sustainability. Massimo Riccaboni University of Florence & CERM, Rome
BIOPHARMACEUTICALS Availability, Diffusion, Sustainability Massimo Riccaboni University of Florence & CERM, Rome The need for a precise definition of biopharmaceutical products Since the 1980s, the general
More information9:15-9:30 WELCOME Paula Alves (Conference Chair) & Lino Ferreira (SPCE-TC President)
Scientific Programme DAY 1 - Thursday, 15 th October, 2015 8:30-13:00 REGISTRATION Set up of posters and exhibition area 9:15-9:30 WELCOME Paula Alves (Conference Chair) & Lino Ferreira (SPCE-TC President)
More informationSchool of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationLeading The Way in Life Science Technologies. Planning Calendar
Leading The Way in Life Science Technologies 2018 Planning Calendar January 1 Reservation: 11/30/17 Material: 12/7/17 l Kinase Assays l Immunotherapy l Stem-Cell Manufacturing Peptalk, January 8 12, San
More informationPost-Baccalaureate Program in Pharmaceutical Science. Accelerate your career
Post-Baccalaureate Program in Pharmaceutical Science Accelerate your career pharmsci.uci.edu pharmsci-grad@uci.edu 949.824.1991 Improve your career options The Post-Baccalaureate Program in Pharmaceutical
More informationSenior Regulatory Affairs Executive AREAS OF EXPERTISE
Senior Regulatory Affairs Executive AREAS OF EXPERTISE More than fifteen years experience in vaccines, pharmaceuticals, biotechnology, and combination device products. Experience in regulatory strategy
More informationSharmila et al. International Journal of Drug Regulatory Affairs; 2017, 5(1), ISSN: Available online at
REGULATORY REQUIREMENTS OF SIMILAR BIOLOGICS FOR MARKETING AUTHORIZATION IN INDIA Available online at www.ijdra.com REVIEW ARTICLE Sharmila Reddy V*, Mounica N.V.N., Anusha S, Evangeline L, Nagabhushanam
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationLeading The Way in Life Science Technologies. Planning Calendar
Leading The Way in Life Science Technologies 2018 Planning Calendar January 1 Reservation: 11/30/17 Material: 12/7/17 l Kinase Assays l Immunotherapy l Stem-Cell Manufacturing Peptalk, January 8 12, San
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationFACULTY OF PHARMACY UNIVERSIDADE DE LISBOA
FACULTY OF PHARMACY UNIVERSIDADE DE LISBOA Presentation This Course enlarges the classical concept of biopharmaceutical sciences by providing scientific, multidisciplinary background on the discovery phase
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 15 July 2010 European Commission Enterprise and Industry Directorate General Consumer Goods, Pharmaceuticals B-1049 Brussels
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationIs a Career in the. Pharmaceutical. Check out our online Student Center to find out more:
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationBiosimilars: The Impact on Academic Pharmacy
Biosimilars: The Impact on Academic Pharmacy George E. MacKinnon III, PhD, MS, RPh, FASHP Founding Dean and Professor College of Pharmacy Vice Provost for Health Sciences Roosevelt University Learning
More informationSetting the Scene - Industry. Regulatory Science. Merete Schmiegelow Senior Director, Regulatory Policy
CORS-Industry-241116 1 Regulatory Science Setting the Scene - Industry Merete Schmiegelow Senior Director, Regulatory Policy Honorary Industrial Ambassador in Regulatory Science at the University of Copenhagen
More informationNon-clinical documentation Overview of Requirements
3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements
More informationPresidential Commission for the Study of Bioethical Issues 2 nd meeting September
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September 13 14 2010 David B. Weiner, Ph.D. Professor Department of Pathology and Laboratory Medicine University of Pennsylvania
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationRare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationBiosimilar Development Clinical Investigator Considerations
Biosimilar Development Clinical Investigator Considerations June 2011 www.ppdi.com Biosimilar products are not new in the pharmaceutical industry. However, the pending expiration of numerous therapeutic
More informationHealthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation
Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)
More informationThe importance of interchangeability in the procurement of medications: Biosimilar case
The importance of interchangeability in the procurement of medications: Biosimilar case ALIMS Congres, Kragujevac, November 6, 2015 Prof. Borut Štrukelj, PhD Brief CV Current position: professor, Pharmaceutical
More informationCERTIFICATE IN BIOPHARMACEUTICALS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers
More informationConsiderations in Product Development with Advanced Therapies and Cancer Vaccines
Considerations in Product Development with Advanced Therapies and Cancer Vaccines Thomas Hinz Head of Section Therapeutic Vaccines Paul-Ehrlich-Institut hinth@pei.de Thomas Hinz, October 29, 2008, San
More informationThe Power to Cure: Therapeutic Innovation in Academia
The Power to Cure: Therapeutic Innovation in Academia Leslie Molony, Ph.D. November 7, 2011 Sanford-Burnham Medical Research Institute: a Non Profit Basic Research Institute Santa Barbara Est. 2006 La
More informationPCWP/HCWP Workshop on personalised medicines: role of patients, consumers and healthcare professionals
13 March 2017 EMA/127118/2017 Stakeholders and Communication Division PCWP/HCWP Workshop on personalised medicines: role of patients, consumers and healthcare professionals Kaisa Immonen Kaisa Immonen
More informationOndaplanetária Presentation
Lisbon, September of 2013 Ondaplanetária Presentation Ondaplanetária, Ondaplanetária, Recrutamento, Formação, Consultoria e Apoio Escolar, Lda, is a Human Resources enterprise working in Portugal. We have
More informationMASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)
MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 1 \ 12 70 2005 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of
More informationEARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS
EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40
More informationEMA s role & responsibility for the development of modern/advanced therapies
EMA s role & responsibility for the development of modern/advanced therapies Agenda Current regulatory picture Overall Regulatory framework New Committee at EMA Current Activities & Challenges Egbert Flory
More informationIR Presentation template [SA, JA, sector]
1 Biotechnology Industry IR Presentation template [SA, JA, sector] Healthcare Sector - Fall 2016 Senior Analyst: Austin Gasparini Junior Analysts: Donavon Young, Marlon Li, Josh Zins Industry Definition
More informationRecent years have witnessed an unprecedented
European Science Foundation Policy Briefing ESF Scientific Forward Look on Nanomedicine February 2005 23 Contents Introduction p. 1 Background Statements and Recommendations 1. Scientific Trends - Nanomaterials
More information